Travis Wilson

Travis Wilson (Gurnet Point Capital)

/ / /

Travis has more than 15 years of investing and executive experience in life sciences and biotechnology. Prior to joining GPC, Travis was President and CEO of Stealth BioTherapeutics (NASDAQ: MITO), a late-stage clinical company developing technologies to treat mitochondrial dysfunction in common and rare diseases.

While CEO and for more than a decade, Travis was a member of the life sciences and biotechnology investment team at the Morningside Group, a privately-held investment firm. As an investor with Morningside, Travis was involved in several successful outcomes, including Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: DRO), Argos (NASDAQ: ARGS), Liquidia (NASDAQ: LQDA), Apellis (NASDAQ: APLS), and ACD (acquired by Bio-Techne).

Travis has also served as a director and board member for multiple biopharmaceutical companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell therapy, neurology, anesthesiology, and ophthalmology. He has lectured extensively on life sciences investing and executive management, and is a long-time supporter of patient-advocacy groups. Travis holds a law degree and a chemical engineering degree, both from the University of Wisconsin.